Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | ATM | Q13315 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227425 | 1.00 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5117118 | 0.98 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5139685 | 0.98 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL229697 | 0.98 | LTA4H (0.90) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5116881 | 0.96 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL491581 | 0.91 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL1776837 | 0.91 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL5856455 | 0.90 | ATM (0.88) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL18824776 | 0.89 | ATM (0.87) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL7139221 | 0.89 | LTA4H (0.75) | LTA4HPTGS2ATML3MBTL1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8258328-B2 | Method and intermediates for preparing 19-norsteroid compounds | AVENTIS PHARMA S.A. (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1622925-B1 | NOVEL METHOD AND INTERMEDIATES FOR THE PREPARATION OF 19-NOR-STEROID COMPOUNDS | AVENTIS PHARMA SA (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-20110046402-A1 | NOVEL METHOD AND INTERMEDIATES FOR PREPARING 19-NORSTEROID COMPOUNDS | AVENTIS PHARMA S.A. (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
| EP-0979076-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO b]THIOPHENES | ELI LILLY AND COMPANY (US) | 2000-02-16 | — | — | EP | disclosed |
| US-6018056-A | Intermediates and processes for preparing benzo (b) thiophenes | ELI LILLY AND COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1998048793-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5643896-A | TREATMENT OF MENOPAUSE SYMPTOMS, OSTEOPOROSIS, CARDIOVASCULAR DISORDERS OR ESTROGEN DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996026935-A1 | 2-BENZYL-3-ARYLBENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1996-09-06 | — | — | WO | disclosed |
| EP-0729955-A1 | 2-Benzyl-3-Arylbenzothiophenes useful for the treatment of post-menopausal syndrome | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5552401-A | CARDIOVASCULAR DISORDERS, OSTEOPOROSIS AND ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5459139-A | Antitumor agents, anticholesterol agents, antiestrogens, treatment of breast cancer | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1995-10-17 | — | — | US | disclosed |
| US-5354861-A | Binds to antiestrogen binding sites; antiproliferative activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | LTA4H 3180/4885PTGS2 2136/4885ATM 3941/4885 |
| US-20110046402-A1 | NOVEL METHOD AND INTERMEDIATES FOR PREPARING 19-NORSTEROID COMPOUNDS | HSD17B7, CYP17A1, HSD17B13 | LTA4H 532/4885PTGS2 1308/4885ATM 4483/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | LTA4H 2984/4885PTGS2 2249/4885ATM 3843/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | LTA4H 3110/4885PTGS2 2657/4885ATM 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.